J.W. Lenders, Q.Y. Duh, G. Eisenhofer et al., Endocrine Society. J. Clin. Endocrinol. Metab. 99, 1915–1942 (2014).
Article CAS PubMed Google Scholar
J.W.M. Lenders, M.N. Kerstens, L. Amar et al., Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the working group on endocrine hypertension of the european society of hypertension. J. Hypertens. 38, 1443–1456 (2020).
Article CAS PubMed PubMed Central Google Scholar
V. Bisogni, L. Petramala, G. Oliviero et al., Analysis of short-term blood pressure variability in pheochromocytoma/paraganglioma patients. Cancers 11(5), 658 (2019).
Article CAS PubMed PubMed Central Google Scholar
H.J. Timmers, F.M. Brouwers, A.R. Hermus et al., Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma. Endocr. Relat. Cancer 15(4), 1127–1133 (2008).
Article CAS PubMed Google Scholar
M. Araujo-Castro, C. Mínguez Ojeda, R. García Centeno et al., Glycemic disorders in patients with pheochromocytomas and sympathetic paragangliomas. Endocr. Relat. Cancer 29(12), 645–655 (2022).
Article CAS PubMed Google Scholar
R. Zhang, D. Gupta, S.G. Albert, Pheochromocytoma as a reversible cause of cardiomyopathy: Analysis and review of the literature. Int. J. Cardiol. 249, 319–323 (2017).
T. Okamura, Y. Nakajima, T. Satoh et al., Changes in visceral and subcutaneous fat mass in patients with pheochromocytoma. Metabolism 64(6), 706–712 (2015).
Article CAS PubMed Google Scholar
M.L. Good, P. Malekzadeh, S.M. Ruff et al., Surgical resection of pheochromocytomas and paragangliomas is associated with lower cholesterol levels. World J. Surg. 44(2), 552–560 (2020).
Article PubMed PubMed Central Google Scholar
T. Zelinka, O. Petrak, H. Turkova et al., High incidence of cardiovascular complications in pheochromocytoma. Hormone Metab. Res. 44, 379–384 (2012).
R.F. Stolk, C. Bakx, J. Mulder et al., Is the excess cardiovascular morbidity in pheochromocytoma related to blood pressure or to catecholamines?. J. Clin. Endocr. Metab. 98, 1100–1106 (2013).
Article CAS PubMed Google Scholar
H. Berent, K. Kuczyńska, B. Wocial et al., Lipids and beta-thromboglobulin in patients with pheochromocytoma. J. Clin. Hypertens. 3(4), 389–396 (1987).
J.J. Li, S.P. Zhao, D. Zhao et al., 2023 Chinese guideline for lipid management. Front. Pharmacol. 14, 1190934 (2023).
Article CAS PubMed PubMed Central Google Scholar
X.F. Pan, L. Wang, A. Pan, Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol. 9(6), 373–392 (2021).
N.M. Neary, K.S. King, K. Pacak, Drugs and pheochromocytoma——don’t Be fooled by every elevated metanephrine. N. Engl. J. Med. 364(23), 2268–2270 (2011).
Article CAS PubMed PubMed Central Google Scholar
G. Eisenhofer, C. Pamporaki, J.W.M. Lenders, Biochemical assessment of pheochromocytoma and paraganglioma. Endocr. Rev. 44(5), 862–909 (2023).
A. Tanabe, A. Ichihara, Nihon rinsho. Japanese J. Clin. Med. 70(Suppl 5), 153–157 (2012).
J.W. Jocken, E.E. Blaak, Catecholamine-induced lipolysis in adipose tissue and skeletal muscle in obesity. Physiol. Behav. 94, 219–230 (2008).
Article CAS PubMed Google Scholar
D. Steinberg, J.K. Huttunen, The role of cyclic AMP in activation of hormone-sensitive lipase of adipose tissue. Adv. Cycl. Nucleotide Res. 1, 47–62 (1972).
D. Langin, A. Dicker, G. Tavernier et al., Adipocyte lipases and defect of lipolysis in human obesity. Diabetes 54, 3190–3197 (2005).
Article CAS PubMed Google Scholar
M. Rydén, J. Jocken, V. van Harmelen et al., Comparative studies of the role of hormone-sensitive lipase and adipose triglyceride lipase in human fat cell lipolysis. Am. J. Physiol. Endocrinol. Metab. 292, E1847–E1855 (2007).
G.F. Grabner, H. Xie, M. Schweiger, R. Zechner, Lipolysis: cellular mechanisms for lipid mobilization from fat stores. Nat. Metab. 3(11), 1445–1465 (2021). https://doi.org/10.1038/s42255-021-00493-6.
Comments (0)